Pharma Journalist 8887 posts 0 comments

Biogen Inc. announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE (zuranolone) as a treatment for postpartum depression (PPD) in adults following…
Read More...

VectorY Therapeutics and Shape Therapeutics Inc. have announced a new partnership aimed at advancing gene therapies for neurodegenerative diseases. Under an option and license…
Read More...

Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), has signed a partnership agreement with MindImmune Therapeutics to support the development of…
Read More...

The New England Journal of Medicine has published the results from Novo Nordisk’s OASIS 4 Phase 3 trial, marking a major advance in obesity treatment with the investigational once-daily…
Read More...

GSK plc announced plans to invest $30 billion in the United States over the next five years, focusing on research and development and supply chain infrastructure. This major investment…
Read More...

Mabwell (Shanghai) Bioscience Co., Ltd. and Aditum Bio have announced the formation of a new biotech company, Kalexo Bio, focused on developing RNA-based therapies for cardiovascular…
Read More...

Adagene Inc. has announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene’s SAFEbody technology to create a third masked…
Read More...

Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on next-generation psychedelic-inspired therapies for mental health, announced the final closing of its Series A…
Read More...

VarmX, a biotech company specializing in treatments for patients on direct oral anticoagulants targeting activated factor Xa (FXa DOACs), has entered a strategic collaboration with…
Read More...

Raludotatug deruxtecan (R-DXd), a novel CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and Merck, has received Breakthrough Therapy Designation (BTD) from the U.S.…
Read More...